Phagocytosis of Killed Tumor Cells Cross-Presentation Through

Total Page:16

File Type:pdf, Size:1020Kb

Phagocytosis of Killed Tumor Cells Cross-Presentation Through A Critical Role for Granzymes in Antigen Cross-Presentation through Regulating Phagocytosis of Killed Tumor Cells This information is current as Sabine Hoves, Vivien R. Sutton, Nicole M. Haynes, Edwin of September 24, 2021. D. Hawkins, Daniel Fernández Ruiz, Nikola Baschuk, Karin A. Sedelies, Maximilian Schnurr, John Stagg, Daniel M. Andrews, Jose A. Villadangos and Joseph A. Trapani J Immunol 2011; 187:1166-1175; Prepublished online 27 June 2011; Downloaded from doi: 10.4049/jimmunol.1001670 http://www.jimmunol.org/content/187/3/1166 Supplementary http://www.jimmunol.org/content/suppl/2011/06/27/jimmunol.100167 http://www.jimmunol.org/ Material 0.DC1 References This article cites 42 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/187/3/1166.full#ref-list-1 Why The JI? Submit online. by guest on September 24, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology A Critical Role for Granzymes in Antigen Cross-Presentation through Regulating Phagocytosis of Killed Tumor Cells Sabine Hoves,*,† Vivien R. Sutton,* Nicole M. Haynes,‡ Edwin D. Hawkins,x Daniel Ferna´ndez Ruiz,{ Nikola Baschuk,‡ Karin A. Sedelies,* Maximilian Schnurr,† John Stagg,‡ Daniel M. Andrews,‡ Jose A. Villadangos,‖ and Joseph A. Trapani*,# Granzymes A and B (GrAB) are known principally for their role in mediating perforin-dependent death of virus-infected or ma- lignant cells targeted by CTL. In this study, we show that granzymes also play a critical role as inducers of Ag cross-presentation by dendritic cells (DC). This was demonstrated by the markedly reduced priming of naive CD8+ T cells specific for the model Ag OVA both in vitro and in vivo in response to tumor cells killed in the absence of granzymes. Reduced cross-priming was due to impairment of phagocytosis of tumor cell corpses by CD8a+ DC but not CD8a2 DC, demonstrating the importance of granzymes in inducing the exposure of prophagocytic “eat-me” signals on the dying target cell. Our data reveal a critical and previously Downloaded from unsuspected role for granzymes A and B in dictating immunogenicity by influencing the mode of tumor cell death and indicate that granzymes contribute to the efficient generation of immune effector pathways in addition to their well-known role in apoptosis induction. The Journal of Immunology, 2011, 187: 1166–1175. umor cell death induced by various agents can activate inflammation due to secretion of anti-inflammatory cytokines such http://www.jimmunol.org/ the immune system and generate an Ag-specific response as TGF-b or IL-10 and transcriptional repression of IL-12p35 in T against the tumor, a concept known as immunogenic cell phagocytes, and uptake of necrotic cells is associated with in- death. The induction of immunogenic cell death is studied using duction of an immune response (6, 7). However, immunogenic cell chemotherapeutic drugs, Ab treatment, irradiation, or repeated death has been described to occur as a result of preapoptotic freeze–thaw cycles (1). The in vivo clearance of dead cells is events in response to drug treatment or irradiation (8, 9). Simi- mainly mediated by macrophages, but their engulfment by den- larly, the engulfment of primary or secondary necrotic material dritic cells (DC) and subsequent Ag processing is critical for can lead to an immune response against cellular Ags in some but cross-presentation of cellular Ags. In vitro and in vivo studies not all experimental settings (5, 10–12). revealed a central role for the CD8a+ DC subset in phagocytosis Various laboratories have shown that granzyme A (GrA) and by guest on September 24, 2021 and cross-presentation of cell-associated Ags to prime a specific granzyme B (GrB) activate important and independent cell death CTL response (2–5). The molecular signals associated with vari- pathways and are instrumental in perforin-dependent killing of ous forms of tumor cell death are known to influence the sub- virus-infected and malignant cells (13, 14). The induction of cell sequent immune response: uptake of apoptotic cells minimizes death by CTL from GrB-deficient mice is marked by reduced DNA fragmentation accompanying target cell apoptosis, but this defect can be compensated by increasing the incubation time (15). *Cancer Cell Death Laboratory, Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne 3002, Victoria, Australia; †Medical Clinic, Ludwig Max- In contrast, apoptosis is not defective in GrA-deficient mice (16). imilian University, 80336 Munich, Germany; ‡Cellular Immunity, Cancer Immunol- We recently showed that both NK cells and CTL from mice de- ogy Program, Peter MacCallum Cancer Centre, Melbourne 3002, Victoria, Australia; x ficient in granzymes A and B (GrAB) induce a unique and phe- Immune Signaling Laboratories, Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne 3002, Victoria, Australia; {Department of Microbiology notypically distinct form of target cell death (17). The cell death and Immunology, University of Melbourne, Melbourne 3010, Victoria, Australia; morphology induced by GrAB-deficient CTL appeared similar to ‖Immunology Department, Walter and Eliza Hall Institute of Medical Research, Melbourne 3050, Victoria, Australia; and #Department of Microbiology and Immu- that induced by wild-type (WT) CTL. However, quantitative and nology, University of Melbourne, Melbourne 3052, Victoria, Australia kinetic live cell microscopy showed that cells dying in response to Received for publication May 19, 2010. Accepted for publication May 24, 2011. GrAB-deficient CTL failed to display phosphatidylserine (PS) on S.H. was supported by a fellowship of the Deutsche Forschungsgemeinschaft (Ho their surfaces. Accordingly, dying cells did not bind annexin V 4007/1-1). J.A.T. and V.R.S. were supported by a program grant from the National until their cell membranes had become permeable to propidium Health and Medical Research Council of Australia (454569). J.A.T. received a senior iodide (PI), indicative of secondary necrosis (17). However, the fellowship from the National Health and Medical Research Council of Australia (288999). E.D.H. and D.M.A. were supported by a Peter Doherty fellowship from functional significance of this finding was not further explored. the National Health and Medical Research Council of Australia. J.S. was supported Studies addressing the role of granzymes in priming an immune by a Canadian Institutes of Health Research fellowship. response have not previously been reported. In this study, we used Address correspondence and reprint requests to Dr. Sabine Hoves and Prof. Ag-specific killing of tumor cells by WT or granzyme-deficient Joseph A. Trapani, Cancer Cell Death Laboratory, Cancer Immunology Program, Peter MacCallum Cancer Centre, St Andrew’s Place, East Melbourne, VIC 3002, CTL to examine the downstream effects of GrAB on generation Australia. E-mail addresses: [email protected] and [email protected] of an immune response. For the first time to our knowledge, we The online version of this article contains supplemental material. show that cell death occurring in the absence of GrAB leads to Abbreviations used in this article: DC, dendritic cell; GrA, granzyme A; GrAB, reduced cross-presentation of a model tumor Ag in vitro and granzymes A and B; GrB, granzyme B; PI, propidium iodide; PS, phosphatidylserine; in vivo. In terms of mechanism, we demonstrate that engulfment of WT, wild-type. tumor cells by DC is critically dependent on the presence of gran- Copyright Ó 2011 by The American Association of Immunologists, Inc. 0022-1767/11/$16.00 zymes. These data define a new and important role of gran- www.jimmunol.org/cgi/doi/10.4049/jimmunol.1001670 The Journal of Immunology 1167 zymes in influencing the quality and magnitude of an immune V-bottom plates. Effector cells were subsequently counterstained with + 2 response. This shows that the mode of CTL-mediated cell death CD8a–PE–Cy7 Ab, and finally a total of 2500 CD8a PI events were influences subsequent target cell phagocytosis and Ag cross- analyzed for CD107a/LAMP-1 exposure. presentation and thus has far more profound effects on immu- Cytokine secretion assay nity than previously recognized. Active secretion of IFN-g from activated GrAB.OT-I or WT.OT-I CTL was determined by commercial cytokine secretion assay (Miltenyi Biotech). Materials and Methods For activation, 5 3 104 CTL were incubated in a target to effector ratio of Mice and reagents 1:5 with either EL-4 or E.G7ova target cells for 3 h, and IFN-g cytokine secretion assay was performed according to the manufacturer’s instruc- C57BL/6 and C57BL/6.bm1 mice were obtained from the Walter and Eliza tions thereafter. CTL were additionally stained with CD8a Ab, and a total 2 + Hall Institute of Medical Research (Melbourne, VIC, Australia). C57BL/6. of 5000 PI CD8a events were analyzed for IFN-g–allophycocyanin se- GrAB mice were originally obtained from M. Simon [Max Planck Institut cretion. fu¨r Immunbiologie, Freiburg, Germany (18)] and were maintained at the Peter MacCallum Cancer Centre and crossed with C57BL/6.OT-I mice OT-I enrichment and CFSE labeling (GrAB.OT-I). Genotype of GrAB.OT-I was confirmed by PCR. Perforin- Naive WT.OT-I CTL were enriched after red cell lysis by depletion using deficient C57BL/6.OT-I mice (Pfp.OT-I) were generated as described CD8+ isolation kit (Miltenyi Biotech).
Recommended publications
  • Nanosecond-Pulsed DBD Plasma-Generated Reactive Oxygen Species Trigger Immunogenic Cell Death in A549 Lung Carcinoma Cells Through Intracellular Oxidative Stress
    International Journal of Molecular Sciences Article Nanosecond-Pulsed DBD Plasma-Generated Reactive Oxygen Species Trigger Immunogenic Cell Death in A549 Lung Carcinoma Cells through Intracellular Oxidative Stress Abraham Lin 1, Billy Truong 1, Sohil Patel 1, Nagendra Kaushik 2, Eun Ha Choi 2, Gregory Fridman 1, Alexander Fridman 1 and Vandana Miller 1,* 1 C. & J. Nyheim Plasma Institute, Drexel University, Philadelphia, PA 19104, USA; [email protected] (A.L.); [email protected] (B.T.); [email protected] (S.P.); [email protected] (G.F.); [email protected] (A.F.) 2 Plasma Bioscience Research Center, Kwangwoon University, Seoul 139791, Korea; [email protected] (N.K.); [email protected] (E.H.C.) * Correspondence: [email protected]; Tel.: +1-215-571-4074 Academic Editor: Hsueh-Wei Chang Received: 1 March 2017; Accepted: 28 April 2017; Published: 3 May 2017 Abstract: A novel application for non-thermal plasma is the induction of immunogenic cancer cell death for cancer immunotherapy. Cells undergoing immunogenic death emit danger signals which facilitate anti-tumor immune responses. Although pathways leading to immunogenic cell death are not fully understood; oxidative stress is considered to be part of the underlying mechanism. Here; we studied the interaction between dielectric barrier discharge plasma and cancer cells for oxidative stress-mediated immunogenic cell death. We assessed changes to the intracellular oxidative environment after plasma treatment and correlated it to emission of two danger signals: surface-exposed calreticulin and secreted adenosine triphosphate. Plasma-generated reactive oxygen and charged species were recognized as the major effectors of immunogenic cell death. Chemical attenuators of intracellular reactive oxygen species successfully abrogated oxidative stress following plasma treatment and modulated the emission of surface-exposed calreticulin.
    [Show full text]
  • Killing Cancer Cells, Twice with One Shot
    Cell Death and Differentiation (2014) 21, 1–2 & 2014 Macmillan Publishers Limited All rights reserved 1350-9047/14 www.nature.com/cdd Editorial Killing cancer cells, twice with one shot ME Bianchi*,1 Cell Death and Differentiation (2014) 21, 1–2; doi:10.1038/cdd.2013.147 I can still remember lecturing that chemotherapy and radio- shows that transglutaminase (TG) 2, a protein with several therapy are effective because they kill cancer cells. That was complex activities, can prevent calreticulin exposure on the simple enough, and when I wanted to make it a bit more cell surface, and therefore TG2-overexpressing cancer cells complex, I ventured into explaining how they mainly killed can escape activation of the immune system.9 cancer cells because they divided much more than other cells, Curiously, calreticulin is also surface exposed by spermato- and how the killing involved apoptosis. Things have moved on zoa, both in mammals and nematodes, to facilitate fertiliza- quite a bit since then. Evidence accumulated in the past few tion. Following the phylogenetic trail to its widest extent, years indicates that some anti-cancer drugs do not kill cancer Sukkurwala et al.10 show that yeast calreticulin, CNE1 protein, cells, but merely push them into senescence, some do kill is surface exposed following ER stress, and facilitates yeast cells but not via apoptosis, and some do kill cells via apoptosis mating too.10 The binding of yeast pheromone a-factor to its G but that is not the main ingredient in their efficacy. protein-coupled receptor (GPCR) induces CNE1 surface The main theme of this issue is that dying cancer cells presentation.
    [Show full text]
  • Stress-Induced Inflammation Evoked by Immunogenic Cell Death Is
    www.nature.com/cdd ARTICLE OPEN Stress-induced inflammation evoked by immunogenic cell death is blunted by the IRE1α kinase inhibitor KIRA6 through HSP60 targeting Nicole Rufo1,2, Dimitris Korovesis3,Sofie Van Eygen1,2, Rita Derua4, Abhishek D. Garg 1, Francesca Finotello5, Monica Vara-Perez1,2, ž 6,7 2,8 9 7,10 11 6 Jan Ro anc , Michael Dewaele , Peter A. de Witte , Leonidas G. Alexopoulos✉ , Sophie Janssens , Lasse Sinkkonen , Thomas Sauter6, Steven H. L. Verhelst 3,12 and Patrizia Agostinis 1,2 © The Author(s) 2021 Mounting evidence indicates that immunogenic therapies engaging the unfolded protein response (UPR) following endoplasmic reticulum (ER) stress favor proficient cancer cell-immune interactions, by stimulating the release of immunomodulatory/ proinflammatory factors by stressed or dying cancer cells. UPR-driven transcription of proinflammatory cytokines/chemokines exert beneficial or detrimental effects on tumor growth and antitumor immunity, but the cell-autonomous machinery governing the cancer cell inflammatory output in response to immunogenic therapies remains poorly defined. Here, we profiled the transcriptome of cancer cells responding to immunogenic or weakly immunogenic treatments. Bioinformatics-driven pathway analysis indicated that immunogenic treatments instigated a NF-κB/AP-1-inflammatory stress response, which dissociated from both cell death and UPR. This stress-induced inflammation was specifically abolished by the IRE1α-kinase inhibitor KIRA6. Supernatants from immunogenic chemotherapy and KIRA6 co-treated cancer cells were deprived of proinflammatory/chemoattractant factors and failed to mobilize neutrophils and induce dendritic cell maturation. Furthermore, KIRA6 significantly reduced the in vivo vaccination potential of dying cancer cells responding to immunogenic chemotherapy. Mechanistically, we found that the anti-inflammatory effect of KIRA6 was still effective in IRE1α-deficient cells, indicating a hitherto unknown off-target effector of this IRE1α-kinase inhibitor.
    [Show full text]
  • Pathogen Response-Like Recruitment and Activation of Neutrophils by Sterile Immunogenic Dying Cells Drives Neutrophil-Mediated Residual Cell Killing
    Cell Death and Differentiation (2017) 24, 832–843 & 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 1350-9047/17 www.nature.com/cdd Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing Abhishek D Garg*,1,2, Lien Vandenberk3, Shentong Fang4, Tekele Fasche4, Sofie Van Eygen1, Jan Maes5, Matthias Van Woensel6,7, Carolien Koks3, Niels Vanthillo5, Norbert Graf8, Peter de Witte5, Stefaan Van Gool9, Petri Salven4 and Patrizia Agostinis*,1 Innate immune sensing of dying cells is modulated by several signals. Inflammatory chemokines-guided early recruitment, and pathogen-associated molecular patterns-triggered activation, of major anti-pathogenic innate immune cells like neutrophils distinguishes pathogen-infected stressed/dying cells from sterile dying cells. However, whether certain sterile dying cells stimulate innate immunity by partially mimicking pathogen response-like recruitment/activation of neutrophils remains poorly understood. We reveal that sterile immunogenic dying cancer cells trigger (a cell autonomous) pathogen response-like chemokine (PARC) signature, hallmarked by co-release of CXCL1, CCL2 and CXCL10 (similar to cells infected with bacteria or viruses). This PARC signature recruits preferentially neutrophils as first innate immune responders in vivo (in a cross-species, evolutionarily conserved manner; in mice and zebrafish). Furthermore, key danger signals emanating from these dying cells, that is, surface calreticulin, ATP and nucleic acids stimulate phagocytosis, purinergic receptors and toll-like receptors (TLR) i.e. TLR7/8/9-MyD88 signaling on neutrophil level, respectively. Engagement of purinergic receptors and TLR7/8/9-MyD88 signaling evokes neutrophil activation, which culminates into H2O2 and NO-driven respiratory burst-mediated killing of viable residual cancer cells.
    [Show full text]
  • Α-TEA's Tumor Toxicity May Be Attributed to Its Capability of Inducing Oxidative Damage in the Endoplasmic Reticulum
    Portland State University PDXScholar University Honors Theses University Honors College 2015 α-TEA's Tumor Toxicity may be Attributed to its Capability of Inducing Oxidative Damage in the Endoplasmic Reticulum Diego Mathias Barragan Echenique Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/honorstheses Let us know how access to this document benefits ou.y Recommended Citation Barragan Echenique, Diego Mathias, "α-TEA's Tumor Toxicity may be Attributed to its Capability of Inducing Oxidative Damage in the Endoplasmic Reticulum" (2015). University Honors Theses. Paper 124. https://doi.org/10.15760/honors.172 This Thesis is brought to you for free and open access. It has been accepted for inclusion in University Honors Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. α-TEA’s Tumor Toxicity may be Attributed to its Capability of Inducing Oxidative Damage in the Endoplasmic Reticulum by Diego Mathias Barragan Echenique An undergraduate honors thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Science in University Honors and Biology Thesis Adviser William L. Redmond, PhD Portland State University 2015 Abstract α-tocopherol ether linked acetic acid (α-TEA) is a Vitamin E derivative with antineoplastic and anti-metastatic properties, tumor specificity, and immunogenic characteristics. The compound is structurally similar to vitamin E, however a key difference is that it doesn’t retain any antioxidant properties. Interestingly, orally administered α-TEA appears to stimulate anti-tumor immunity, which, along with its anti-metastatic and antineoplastic properties, makes the molecule’s mechanism of action worth investigating.
    [Show full text]
  • Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion
    cancers Review Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion Andromachi Kotsafti 1 , Marco Scarpa 2 , Ignazio Castagliuolo 3 and Melania Scarpa 1,* 1 Laboratory of Advanced Translational Research, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy; [email protected] 2 General Surgery Unit, Azienda Ospedaliera di Padova, 35128 Padua, Italy; [email protected] 3 Department of Molecular Medicine DMM, University of Padua, 35121 Padua, Italy; [email protected] * Correspondence: [email protected] Received: 8 June 2020; Accepted: 28 June 2020; Published: 1 July 2020 Abstract: The immune system is a crucial regulator of tumor biology with the capacity to support or inhibit cancer development, growth, invasion and metastasis. Emerging evidence show that reactive oxygen species (ROS) are not only mediators of oxidative stress but also players of immune regulation in tumor development. This review intends to discuss the mechanism by which ROS can affect the anti-tumor immune response, with particular emphasis on their role on cancer antigenicity, immunogenicity and shaping of the tumor immune microenvironment. Given the complex role that ROS play in the dynamics of cancer-immune cell interaction, further investigation is needed for the development of effective strategies combining ROS manipulation and immunotherapies for cancer treatment. Keywords: reactive oxygen species; oxidative stress; immunity; inflammation; cancer 1. Introduction Reactive oxygen species (ROS) are defined as chemically reactive derivatives of oxygen that elicits both harmful and beneficial effects in cells depending on their concentration. Oxidative stress occurs when ROS production overcomes the scavenging potential of cells or when the antioxidant response is severely impaired; as a consequence nonradical and free radical ROS such as hydrogen peroxide (H2O2), the superoxide radical (O2•) or the hydroxyl radical (OH•) accumulate [1].
    [Show full text]
  • Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy
    cancers Article Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy Kevin Chih-Yang Huang 1,2 , Shu-Fen Chiang 3,4, Pei-Chen Yang 4, Tao-Wei Ke 5,6, Tsung-Wei Chen 7,8, Ching-Han Hu 4, Yi-Wen Huang 4, Hsin-Yu Chang 4, William Tzu-Liang Chen 5,9,10,* and K. S. Clifford Chao 4,8,11,* 1 Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung 40402, Taiwan; [email protected] 2 Translation Research Core, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan 3 Lab of Precision Medicine, Feng-Yuan Hospital, Ministry of Health and Welfare, Taichung 42055, Taiwan; [email protected] 4 Cancer Center, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan; [email protected] (P.-C.Y.); [email protected] (C.-H.H.); [email protected] (Y.-W.H.); [email protected] (H.-Y.C.) 5 Department of Colorectal Surgery, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan; [email protected] 6 School of Chinese Medicine & Graduate Institute of Chinese Medicine, China Medical University, Taichung 40402, Taiwan Citation: Huang, K.C.-Y.; 7 Department of Pathology, Asia University Hospital, Asia University, Taichung 41354, Taiwan; Chiang, S.-F.; Yang, P.-C.; Ke, T.-W.; [email protected] Chen, T.-W.; Hu, C.-H.; Huang, Y.-W.; 8 Graduate Institute of Biomedical Science, China Medical University, Taichung 40402, Taiwan Chang, H.-Y.; Chen, W.T.-L.; 9 Department of Surgery, School of Medicine, China Medical University, Taichung 40402, Taiwan Chao, K.S.C.
    [Show full text]
  • The Role of Immunogenic Cell Death
    cancers Review Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death 1, 2, 1 3 4 Zahra Asadzadeh y, Elham Safarzadeh y, Sahar Safaei , Ali Baradaran , Ali Mohammadi , Khalil Hajiasgharzadeh 1 , Afshin Derakhshani 1 , Antonella Argentiero 5, Nicola Silvestris 5,6,* and Behzad Baradaran 1,7,* 1 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, Iran; [email protected] (Z.A.); [email protected] (S.S.); [email protected] (K.H.); [email protected] (A.D.) 2 Department of Immunology and Microbiology, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil 5618985991, Iran; [email protected] 3 Research & Development Lab, BSD Robotics, 4500 Brisbane, Australia; [email protected] 4 Department of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark; [email protected] 5 IRCCS Istituto Tumori “Giovanni Paolo II” of Bari, 70124 Bari, Italy; [email protected] 6 Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”, 70124 Bari, Italy 7 Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran * Correspondence: [email protected] (N.S.); [email protected] (B.B.); Tel.: +98-413-337-1440 (B.B.) The first two authors contributed equally to this work. y Received: 12 March 2020; Accepted: 17 April 2020; Published: 23 April 2020 Abstract: Cell death resistance is a key feature of tumor cells. One of the main anticancer therapies is increasing the susceptibility of cells to death. Cancer cells have developed a capability of tumor immune escape.
    [Show full text]
  • RIG-I-Like Helicases Induce Immunogenic Cell Death of Pancreatic Cancer Cells and Sensitize Tumors Toward Killing by CD8 Þ T Cells
    Cell Death and Differentiation (2014) 21, 1825–1837 & 2014 Macmillan Publishers Limited All rights reserved 1350-9047/14 www.nature.com/cdd RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8 þ T cells This article has been corrected since Online Publication and a corrigendum appears in this issue P Duewell1,2, A Steger1, H Lohr1, H Bourhis1, H Hoelz1, SV Kirchleitner1, MR Stieg1, S Grassmann1, S Kobold1, JT Siveke3, S Endres1 and M Schnurr*,1,2 Pancreatic cancer is characterized by a microenvironment suppressing immune responses. RIG-I-like helicases (RLH) are immunoreceptors for viral RNA that induce an antiviral response program via the production of type I interferons (IFN) and apoptosis in susceptible cells. We recently identified RLH as therapeutic targets of pancreatic cancer for counteracting immunosuppressive mechanisms and apoptosis induction. Here, we investigated immunogenic consequences of RLH-induced tumor cell death. Treatment of murine pancreatic cancer cell lines with RLH ligands induced production of type I IFN and proinflammatory cytokines. In addition, tumor cells died via intrinsic apoptosis and displayed features of immunogenic cell death, such as release of HMGB1 and translocation of calreticulin to the outer cell membrane. RLH-activated tumor cells led to activation of dendritic cells (DCs), which was mediated by tumor-derived type I IFN, whereas TLR, RAGE or inflammasome signaling was dispensable. Importantly, CD8a þ DCs effectively engulfed apoptotic tumor material and cross-presented tumor- associated antigen to naive CD8 þ T cells. In comparison, tumor cell death mediated by oxaliplatin, staurosporine or mechanical disruption failed to induce DC activation and antigen presentation.
    [Show full text]
  • Profiling the Immunogenic Cell Death (ICD)
    Profiling the immunogenic cell death (ICD) mechanisms induced by Nano-Pulse Stimulation (NPS) treatment in mouse B16-F10 melanoma tumors using NanoString technology Amanda McDaniel, Snjezana Anand, Aman Alzubier, Juliette Berlin, Holly Hartman, Darrin Uecker and Richard Nuccitelli Pulse Biosciences, 3957 Point Eden Way, Hayward, CA 94545 Background Results Nano-Pulse Stimulation (NPS) is a non-thermal tumor therapy NPS Treatment Tumor cell releasing DAMPs binding to DC phagocytosing Mature T-cell Figures 1a-b. receptors on an immature DC tumor cell DC that delivers ultrashort electrical pulses (100-600ns) to tumor a. CD8+ cells. NPS opens nanopores in the membrane of the ER, NPS-induced T-cell immune 2+ allowing the efflux of Ca into the cytoplasm, causing ER response stress and the production of ROS. These effects induce an CD4+ immunogenic cell death (ICD)1 that both eliminates a primary T-cell tumor and inhibits the growth of a secondary re-challenge DAMPs Release – PRR Binding Adaptive Immune Response (AIR) Priming T cell Activation tumor in preclinical models2. To date, the primary mechanism b. Cell Death of action of most known ICD inducers is ER stress and ROS PERK Ire1 IP3R Casp12 CD86 Calr Ifng Lrp1 CD28 Il2 Il1b production leading to intrinsic mitochondrial apoptosis, and the Traf2 Ifna1 Casp8 Casp3 Ifnb1 eIF2α P2rx7 Nlrp3 release and translocation of damage associated molecular ASK1 CD80 Ifngr1 Casp1 Il1r1 4-6 Cd4 patterns (DAMPs) that bind to pattern recognition receptors Il6 Il6ra Atf4 JNK Casp7 Foxp3 Tlr4 Ifnar1 (PRRs) to prime the adaptive immune response. Here we Hmgb1 Tnf Il12a Il12rb1 Casp9 Ly96 Cd8a sought to profile the pathways involved in ER stress, apoptotic CHOP CytC Apaf1 Myd88 Il12b Il12rb2 Cd8b1 cell death and the immune response after NPS treatment, Figures 2a-d.
    [Show full text]
  • Insights Into Immunogenic Cell Death in Onco-Therapies
    cancers Review Restoring the Immunity in the Tumor Microenvironment: Insights into Immunogenic Cell Death in Onco-Therapies Ángela-Patricia Hernández 1 , Pablo Juanes-Velasco 1 , Alicia Landeira-Viñuela 1, Halin Bareke 1,2, Enrique Montalvillo 1, Rafael Góngora 1 and Manuel Fuentes 1,3,* 1 Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, Spain; [email protected] (Á.-P.H.); [email protected] (P.J.-V.); [email protected] (A.L.-V.); [email protected] (H.B.); [email protected] (E.M.); [email protected] (R.G.) 2 Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Institute of Health Sciences, Marmara University, 34722 Istanbul, Turkey 3 Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, Spain * Correspondence: [email protected]; Tel.: +34-923-294-811 Simple Summary: Since the role of immune evasion was included as a hallmark in cancer, the idea of cancer as a single cell mass that replicate unlimitedly in isolation was dissolved. In this sense, cancer and tumorigenesis cannot be understood without taking into account the tumor microenvironment (TME) that plays a crucial role in drug resistance. Immune characteristics of TME can determine the success in treatment at the same time that antitumor therapies can reshape the immunity in TME. Here, we collect a variety of onco-therapies that have been demonstrated to induce an interesting Citation: Hernández, Á.-P.; immune response accompanying its pharmacological action that is named as “immunogenic cell Juanes-Velasco, P.; Landeira-Viñuela, death”. As this report shows, immunogenic cell death has been gaining importance in antitumor A.; Bareke, H.; Montalvillo, E.; therapy and should be studied in depth as well as taking into account other applications that may Góngora, R.; Fuentes, M.
    [Show full text]
  • Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: the Calreticulin Exposure Pathway
    Published OnlineFirst April 26, 2010; DOI: 10.1158/1078-0432.CCR-09-2891 Published OnlineFirst on May 25, 2010 as 10.1158/1078-0432.CCR-09-2891 Molecular Pathways Clinical Cancer Research Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway Laurence Zitvogel1,2,3, Oliver Kepp2,3,4, Laura Senovilla2,3,4, Laurie Menger2,3,4, Nathalie Chaput1,2,3, and Guido Kroemer2,3,4 Abstract In response to some chemotherapeutic agents such as anthracyclines and oxaliplatin, cancer cells un- dergo immunogenic apoptosis, meaning that their corpses are engulfed by dendritic cells and that tu- mor cell antigens are presented to tumor-specific CD8+ T cells, which then control residual tumor cells. One of the peculiarities of immunogenic apoptosis is the early cell surface exposure of calreticulin (CRT), a protein that usually resides in the lumen of the endoplasmic reticulum (ER). When elicited by anthracyclines or oxaliplatin, the CRT exposure pathway is activated by pre-apoptotic ER stress and the phosphorylation of the eukaryotic translation initiation factor eIF2α by the kinase PERK, followed by caspase-8-mediated proteolysis of the ER-sessile protein BAP31, activation of the pro-apoptotic pro- teins Bax and Bak, anterograde transport of CRT from the ER to the Golgi apparatus and exocytosis of CRT-containing vesicles, finally resulting in CRT translocation onto the plasma membrane surface. In- terruption of this complex pathway abolishes CRT exposure, annihilates the immunogenicity of apo- ptosis, and reduces the immune response elicited by anticancer chemotherapies. We speculate that human cancers that are incapable of activating the CRT exposure pathway are refractory to the immune- mediated component of anticancer therapies.
    [Show full text]